Hillhouse Investment Management Ltd

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Hillhouse Investment Management Ltd
CRD #160896
SEC #801-78022
CIK #0001510589
AUM
Employees 344 (35% Investors, 0% Brokers)
Fees
Minimum
Phone656-603-0860
Address8 Marina Boulevard
Singapore, Singapore
Source [IAPD] [EDGAR] [Website] [LinkedIn] [Instagram]
Total AUM ($B)
806448321602010201520212027
In the News
Fri, 08 May 2026 Hillhouse Investment Management to acquire Mercer’s Private Client Services — (Re)in Asia
Fri, 03 Apr 2026 Hillhouse Investment Management Opens Office in Abu Dhabi Amid Regional Tensions — Hubbis
Fees and Compensation — Form ADV Part 2A (3/31/2023) [Brochure]
5, “Fees and Compensation” above for information regarding how HIM is compensated by its
clients, the conflict of interest created by allocating investment opportunities among clients, and
how HIM addresses such conflict of interest.

HIM does not recommend or select third-party investment advisers for its clients. None of HIM,
HHLR, or any other affiliate receives compensation, directly or indirectly, from any of the others
for any recommendation of the other.

However, in certain circumstances, clients could enter into joint ventures with third-party
managers or other persons with respect to the management of specified portfolio investments or
categories of portfolio investments and in connection therewith, such third-party managers or other
persons could receive management fees and/or performance-based compensation such as a carried
interest in vehicles through which such joint ventures invest. Any compensation of such third-
party managers or of joint venture partners that will reduce a client’s returns from the relevant
portfolio investments will not offset carried interest or management fees paid to HIM and will
increase the cost of the investors’ investment in clients.

Warehoused Investment. During the term of a client, the general partner (or similar controlling
entity) of such client or any of its affiliates could initially purchase all or part of an investment
intended to be made by such client or fund the purchase of, make a cornerstone investment in
connection with or provide financing in connection with, all or part of an investment made by such
client if, in each such case, the general partner (or similar controlling entity) of such client
determines that it would be necessary or appropriate, including from a legal, tax or regulatory
standpoint, in order to facilitate the making of such investment by such client. In such situations,
it is generally expected that, (a) the general partner (or similar controlling entity) of such client or
its affiliate (as applicable) could transfer the relevant warehoused investment to such client or (b)
such client could repay the general partner (or similar controlling entity) of such client or its
affiliate (as applicable) for such funding or financing, typically at a price or in an amount (as
applicable) generally equal to the cost of such warehoused investment plus interest thereon or on
such other terms as permitted under such client’s governing documents. In such cases, such client
will pay all closing costs in connection with such warehoused investment, including costs incurred
in connection with the transfer of such warehoused investment to such client (if applicable). There
is no guarantee, however, that such warehoused investment will be transferred to such client at all
(due to legal, tax, regulatory or other reasons), or that the price paid by such client for such
warehoused investment would represent the price that would have been obtained in a transaction
negotiated at arm’s length.

Prior to the initial investment or initial closing of the applicable client, the general partner (or
similar controlling entity) of such client or any of its affiliates could purchase, fund the purchase
of, make a cornerstone investment in connection with or provide financing in connection with one
or more investments to temporarily warehouse such investments for such client. Following the
initial investment or closing of such client, the general partner (or similar controlling entity) of
such client will use commercially reasonable efforts to procure that the general partner (or similar
controlling entity) of such client or its affiliate (as applicable) transfers each such pre-investment
or -closing investment to such client at a price equal to the cost of such investment plus interest
thereon or on such other terms as permitted under such client’s governing documents. In
connection with, or in lieu of, the foregoing, HIM could enter into arrangements with one or more
non-affiliated persons (including any existing investors of any client and potential investors in a
client) whereby such persons agree to initially fund all or a portion of the cost of such pre-initial
investment or pre-closing investments.

There is no guarantee, however, that such pre-initial investment or pre-closing investments will be
transferred to a client at all (due to legal, tax, regulatory or other reasons), or that the price paid by
such client for each such pre-initial investment or pre-closing investment would represent the price
that would have been obtained in a transaction negotiated at arm’s length.

Other conflicts not discussed above are expected arise in connection with HIM’s advisory
business. Investors are urged to consult the offering and other governing documents of the relevant
clients.
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2023) [Brochure]
ITEM 7: TYPES OF CLIENTS

HIM serves as an investment adviser to pooled investment vehicles whose underlying investors
are “accredited investors” (as defined in Rule 501(a) of Regulation D under the U.S. Securities
Act of 1933, as amended) and/or “qualified purchasers” (as defined in Section 2(a)(51) of the U.S.
Investment Company Act of 1940, as amended) and/or “knowledgeable employees” (within the
meaning of Rule 3c-5 under the U.S. Investment Company Act of 1940, as amended). Underlying
investors in the pooled investment vehicles HIM advises include endowments, foundations, non-
profit organizations, pensions, corporates, government entities, family offices, trusts, and other
businesses or institutions. As noted in Item 4, HIM and the other Hillhouse Investment Group
entities also advise non-U.S. accounts and vehicles (including co-investment vehicles) that are not
deemed advisory clients under the Advisers Act and not discussed in this Brochure.

HIM could also provide investment advice to institutional clients such as endowments,
foundations, non-profit organizations, pensions, corporates, government entities, family offices,
trusts, and other businesses or institutions.

Minimum Account Size

Certain of the Funds require a minimum capital commitment or investment amount, but the general
partners of such Funds may accept capital commitments or investment amounts in lesser amounts
in their sole discretion. HIM generally does not require clients or investors to maintain a minimum
investment to continue an advisory relationship or to remain invested in the Funds.

Advisory Agreements

HIM’s clients typically enter into a written investment management, advisory, or similar
agreement (and/or enter into or become subject to a limited partnership or similar organizational
agreement with HIM or one of its affiliates) in establishing an advisory relationship with HIM or
its affiliates. HIM will not assign any advisory agreements without client consent.
CIK Period
0001510589
Sector Form 13F Holdings Value ($B)
Pinduoduo Inc 0.4
Alibaba Group Holding Ltd 0.3
BeiGene Ltd 0.3
FUTU Holdings Ltd 0.2
Legend Biotech Corp 0.1
Arrivent Biopharma Inc 0.1
KE Holdings Inc 0.1
Cytek Biosciences Inc 0.0
Marvell Technology Inc 0.0
I-Mab 0.0
MAZE Therapeutics Inc 0.0
Contineum Therapeutics Inc 0.0
Agora Inc 0.0
Webull Corp 0.0
Taiwan Semiconductor Manufacturing Co Ltd 0.0
Sagimet Biosciences Inc 0.0
TUYA Inc 0.0
General Electric Co 0.0
Vipshop Holdings Ltd 0.0
MOGU Inc 0.0
Gossamer Bio Inc 0.0
Intel Corp 0.0
Pacific Biosciences of California Inc 0.0
Equinox Gold Corp 0.0
Nvidia Corp 0.0
Lumentum Holdings Inc 0.0
Corning Inc /NY 0.0
Barrick Gold Corp 0.0
 
 
 
Prev | Page 1 | Next
Type Form D Funds Date Sold AUM
PE Hillhouse RAVA RAOF II LP 2026-03-31 421.8 M
PE VNTR Investment LP 2024-03-29 0.8 M
PE Hillhouse GBT Fund LP 2023-03-31 169.3 M
PE Hillhouse Hawthorn Venture Opportunities Fund VI LP 2023-03-31 7.4 M
PE Hillhouse Venture Fund VI LP 2023-03-31 169.7 M
PE HH HR Investment LP 2022-03-31 25.9 M
PE Hillhouse Climate Fund LP 2022-03-31 151.7 M
PE Hillhouse Healthcare Fund LP 2022-03-31 368.0 M
PE Hillhouse Real Asset Opportunities Fund LP 2022-03-31 397.0 M
PE Keel Fund I LP 2022-03-31 503.1 M
View All
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 71 62.0
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 71 62.0
By Discretionary
Discretionary 71 62.0
Non-Discretionary 0 0.0
Total 71 62.0
By Non-United States Persons
Non-United States Persons 62.0
United States Persons 0.0
Total 71 62.0
EDGAR Form CIK 2011 - 2026
13F-HR [0001510589]
13F-NT [0001510589]
3 [0001510589]
4 [0001510589]
SC 13D [0001510589]
SC 13G [0001510589]
Form 13D/13G Filer Form 13D/13G Subject Filed
Hillhouse Investment Management Ltd Smart Share Global Ltd [2025-08-20]
Hillhouse Investment Management Ltd Webull Corp [2025-08-14]
Hillhouse Investment Management Ltd Oatly Group AB [2025-05-15]
Hillhouse Investment Management Ltd Cytek Biosciences Inc [2024-11-14]
Hillhouse Investment Management Ltd Hesai Group [2024-02-14]
Hillhouse Investment Management Ltd Sagimet Biosciences Inc [2024-02-14]
Hillhouse Investment Management Ltd TScan Therapeutics Inc [2022-02-14]
Hillhouse Investment Management Ltd Enfusion Inc [2022-02-14]
Hillhouse Investment Management Ltd Legend Biotech Corp [2021-07-12]
Hillhouse Capital Management Ltd Zoom Video Communications Inc [2020-02-14]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI549300QZBUF1P3XCSP76
Form 3/4/5 Subject 2011 - 2026
ArriVent BioPharma Inc
HHLR Advisors Ltd
Hillhouse Investment Management Ltd
BeOne Medicines Ltd
Enfusion Inc
Apellis Pharmaceuticals Inc
China Jo-Jo Drugstores Inc
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
ArriVent BioPharma Inc AVBP
Common Stock
2025-12-10 Sell 555,555 $23.37 12,983,320
BeOne Medicines Ltd BGNE
Ordinary Shares
2024-12-02 Sell 17,842,500 $200.00 3,568,500,000
ArriVent BioPharma Inc AVBP
Series A Preferred Stock · derivative
2024-01-30 Conversion 55,000,000 $0.00
ArriVent BioPharma Inc AVBP
Common Stock
2024-01-30 Conversion 3,616,041
ArriVent BioPharma Inc AVBP
Common Stock
2024-01-30 Buy 555,555 $18.00 9,999,990
ArriVent BioPharma Inc AVBP
Series B Preferred Stock · derivative
2024-01-30 Conversion 4,761,903 $0.00
ArriVent BioPharma Inc AVBP
Common Stock
2024-01-30 Conversion 313,076
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-14 Sell 273,728 $207.72 56,858,780
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-13 Sell 313,400 $128.43 40,249,962
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-13 Sell 611,000 $211.45 129,195,950
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-12 Sell 281,400 $130.83 36,815,562
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-12 Sell 968,812 $213.91 207,238,575
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-09 Sell 328,952 $217.02 71,389,163
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-09 Sell 213,700 $130.35 27,855,795
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-08 Sell 1,163,825 $218.14 253,876,785
BeOne Medicines Ltd BGNE
Ordinary Shares
2022-08-22 Other 7,800 $0.00
Enfusion Inc ENFN
Class A common stock, par value $0.001 per share
2021-10-25 Sell 647,862 $15.90 10,301,006
Apellis Pharmaceuticals Inc APLS
Common Stock
2017-11-13 Conversion 2,098,581
Apellis Pharmaceuticals Inc APLS
Series D Convertible Preferred Stock · derivative
2017-11-13 Conversion 4,476,275 $0.00
Apellis Pharmaceuticals Inc APLS
Common Stock
2017-11-13 Buy 1,428,571 $14.00 19,999,994
showing 20 of 24 most recent transactions
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com